8 October 2020 - Gilead has signed a joint procurement agreement with the European Commission to enable ‘rapid and equitable’ access to its COVID-19 antiviral remdesivir, sold under the brand name Veklury.

This new agreement allows participating countries in the EU, the European Economic Area (EEA) and the UK to purchase Gilead’s drug for both real-time demand and stockpiling needs.

It covers purchases of remdesivir over the next six months with the option to be extended beyond this. This agreement replaces the initial emergency support instrument that enable the European Commission to procure remdesivir for EU member states – including the UK – that ran from August through to October 2020.

Read Pharma Times article